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ABSTRACT
Objective: To investigate the impact of mammalian target of rapamycin (mTOR) 
inhibitor conversion together with minimization of calcineurin inhibitor on allograft 
outcome and patient survival in kidney transplant recipients with post-transplant 
cancers.
Methods: A retrospective study of all kidney transplant recipients diagnosed to 
have post-transplant cancers between the period 1/1/1994 and 30/6/2015. Patients 
were divided into 2 groups: mTOR inhibitor group and non-conversion group. Outcome 
included allograft function, patient survival, graft survival, acute rejection and cancer 
recurrence. 
Results: 115 patients (56 in mTOR inhibitor group and 59 in non-conversion 
group) were analyzed. Median follow up was 28 months (range: 1 month – 20 years). 
The allograft function at 1-year remained similar between both groups. There was 
no significant difference in the patient survival, graft survival and rejection free 
survival between both groups. More patients in the non-conversion group developed 
recurrence of cancers than mTOR inhibitor group but statistically not significant. 
Conclusions: Use of mTOR inhibitors together with calcineurin inhibitor 
minimization offer a reasonable option in kidney transplant recipients who developed 
post-transplant cancers in view of stable renal function, low rejection rate and low 
cancer recurrence rate.
INTRODUCTION
Cancer is an important comorbidity in kidney 
transplantation because the incidence and prevalence of 
post-transplant cancers have increased in the past 10-
15 years [1-3]. Long-term immunosuppression is an 
important contributor to the increased number of post-
transplant cancers. However, it is still not clear how the 
immunosuppressive regimen should be adjusted for those 
patients who developed cancers. Although reduction of 
immunosuppressive agents is widely accepted, there has 
been concern that it may adversely affect the patient and 
allograft survival [4-6]. 
The role of mammalian target of rapamycin (mTOR) 
inhibitors in kidney transplantation has attracted much 
attention because of its dual immunosuppressive and 
antitumor effects [7-10]. However, the role of mTOR 
inhibitors in patients who developed post-transplant 
cancers is less certain. One commonly used strategy is to 
stop the calcineurin inhibitors (CNIs), introduce mTOR 
inhibitors and then minimize the mycophenolate [11]. 
Switching from CNIs to mTOR inhibitors has been shown 
to be associated with regression of post-transplant Kaposi 
sarcoma [12, 13]. In addition, randomization studies also 
showed that conversion from CNIs to sirolimus reduced 
the risk of non-melanoma skin cancer (NMSC) recurrence 
after kidney transplantation [8, 9]. However, complete 
elimination of CNIs may be associated with a greater 
risk of acute or chronic rejection and graft failure. On 
the contrary, minimization of CNI doses in association 
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with mTOR inhibitors seems to be well tolerated without 
increasing the risk of rejection [14]. 
Although there have been some case series 
concerning the use of mTOR inhibitors in kidney 
transplant recipients after cancer diagnosis, the main 
approach in these studies was the elimination of the CNIs. 
On the other hand, information on the use of mTOR 
inhibitors with CNI minimization in post-transplant 
cancers was scarce. Hence we investigate the impact 
of conversion to mTOR inhibitors together with CNI 
minimization on the allograft outcome and patient survival 
in kidney transplant recipients who developed de novo 
cancers.
RESULTS
Total 1227 kidney transplant recipients had 
follow up during the study period and 124 (10.1%) 
of them developed cancers. Among these cancers, 23 
were hematological cancers (all were post-transplant 
lymphoproliferative disorders (PTLD)) and 101 were 
solid organ cancers. The most common sites of solid 
organ cancers included kidney (n = 19), colorectum (n 
= 13), liver (n = 11), lung (n = 10) and breast (n = 6). 
The mean age at transplant was 44.5 +/- 12.1 years and 
the mean age at diagnosis of cancer was 53.8 +/- 12.1 
years. The median duration from transplant to cancer was 
8.8 years (2 months - 26.8 years). The overall mortality 
was 59.7 (74/124) %. The most common causes of death 
were cancer progression (n = 37), followed by sepsis (n 
= 21) and ischemic heart disease (n = 6). On the other 
hand, 19 patients had graft failure (14 due to chronic 
allograft nephropathy, 1 due to acute rejection and 4 due 
to unknown causes). 
In order to study the effects of mTOR inhibitors in 
our cohort, 9 patients were excluded from analysis. Seven 
were on mTOR inhibitors before cancer and 2 had graft 
nephrectomy (one due to renal cell carcinoma and the 
other due to non-Hodgkin lymphoma within the grafts) 
with subsequent withdrawal of immunosuppression. As a 
result, 115 patients were further analyzed (Table 1). The 
median follow up was 28 months (range: 1 month - 20 
years). Fifty-six patients belonged to the mTOR inhibitor 
group (mean follow up 40 +/- 39 months) and 59 belonged 
to the non-conversion group (mean follow up 50 +/- 59 
months). There was no significant difference in the follow-
up duration between both groups (P = 0.26). Their baseline 
demographic and clinical characteristics were depicted in 
Table 2. 
Table 3 showed the immunosuppressive regimen 
before and after diagnosis of cancers in both groups. In 
the mTOR inhibitor group, azathioprine was withdrawn 
in 23 patients while mycophenolate was withdrawn in 19 
patients. On the other hand, only 3 patients had elimination 
Table 1: Number of patients according to the site and stage of cancer.
Sites of cancer
(n = 115)
Localized
(n = 64)
Advanced
(n = 51)
PTLD  5 13
Kidney and ureter 17  3
Bladder  4  0
Prostate  3  1
Testis  1  1
Cervix  3  0
Ovary  1  1
Vulva  1  0
Esophagus  1  1
Stomach  2  2
Colorectum and anus  4  9
Liver  7  4
Pancreas  0  1
Breast  1  4
Lung  3  7
Nasopharynx  0  1
Oral cavity and tongue  1  1
Thyroid  3  0
NMSC  4  0
Melanoma  1  0
KS  2  2
KS: Kaposi sarcoma; NMSC: non melanoma skin cancer; PTLD: post-transplant lymphoproliferative disorders; 
Definition of localized and advanced disease shown in the Material and Methods section.
Oncotarget44835www.impactjournals.com/oncotarget
of CNIs. They were then replaced immediately with 
mTOR inhibitors (sirolimus in 35 patients and everolimus 
in 21 patients). As a result, 53 patients (94.6%) were on 
prednisolone + CNI + mTOR inhibitor regimen and 3 
(5.4%) patients were on prednisolone + mTOR inhibitors. 
The dose of CNIs was substantially reduced after the 
diagnosis of cancer. On the other hand, azathioprine was 
withdrawn in 9 patients and mycophenolate in 3 patients 
in the non-conversion group. Although a smaller dose 
of CNIs was also used in the non-conversion group, the 
dose reduction of CNIs was not as much as that in the 
mTOR inhibitor group. As a result, the trough levels of 
both cyclosporine and tacrolimus were significantly lower 
in the mTOR inhibitor group (Table 4). The trough level 
of sirolimus was 8.2 +/- 2.1 ng/mL while the trough level 
of everolimus was 4.9 +/- 1.2 ng/mL. 
Renal function remained similar between both 
groups before cancer development and 1 year after cancer 
(Table 4). If only those patients with eGFR > 30 ml/
min/1.73m2 were analyzed, the eGFR at 1 year was better 
in mTOR inhibitor group (n = 41) than non-conversion 
group (n = 27) although it was not statistically significant 
(61 vs 58 ml/min/1.73m2, P = 0.70). Only 4 patients in 
our cohort developed biopsy proven acute rejection after 
cancer (2 in each group). Two had type 1A acute cellular 
rejection, 1 had acute antibody-mediated rejection and 1 
had borderline acute rejection. There was no significant 
difference in the rejection free survival between both 
groups (P = 0.48). More patients (7/59, 11.9%) in the non-
conversion group developed recurrence of cancers than 
mTOR inhibitor group (3/56, 5.4%). However, there was 
no significant difference in the disease free survival (P = 
0.26, Figure 1). 
Total 71 patients (28 in mTOR inhibitor group and 
43 in non-conversion group) died during the follow up 
period. Twelve patients in the mTOR inhibitor group and 
24 in the non-conversion group died of cancer progression. 
In the mTOR inhibitor group, all patients who died of 
Table 2: Demographic and clinical characteristics of patients with and without conversion to mTOR inhibitor-based 
therapy.
mTOR inhibitor
(n = 56)
Non-conversion
(n = 59) P value
Age at cancer (years) 54.6 +/- 10.7 53.6 +/- 12.7 0.64
Age at transplant (years) 44.6 +/- 11.8 44.8 +/- 12.3 0.94
Duration from transplant to cancer (years) 9.9 +/- 6.5 8.9 +/- 7.2 0.39
Male, n (%) 36 (64.3) 31 (52.5) 0.20
Causes of ESRD, n (%)
Glomerulonephritis
Diabetes
Hypertension
Unknown
Others
27 (48.2)
5 (8.9)
6 (10.7)
6 (10.7)
12 (21.5)
29 (49.2)
2 (3.4)
3 (5.1)
10 (16.9)
15 (25.4)
0.46
Deceased / Living transplant, n (%) 45 (80.4) / 11 (19.6) 52 (88.1) / 7 (11.9) 0.25
First / Second transplant, n (%) 53 (94.6) / 3 (5.4) 58 (98.3) / 1 (1.7) 0.28
Biopsy proven rejection before cancers, n (%) 15 (26.8) 17 (29.8) 0.81
Localized / Advanced, n (%) 32 (57.1) / 24 (42.9) 32 (54.2) / 27 (45.8) 0.74
Hematological / Solid organ cancers, n (%) 11 (19.6) / 45 (80.4) 7 (11.9) / 52 (88.1) 0.25
Induction therapy, n (%) 7 (12.5) 13 (22.0) 0.18
CNI therapy, n (%)
 Cyclosporine
 Tacrolimus
36 (64.3)
20 (35.7)
43 (72.9)
16 (27.1)
0.32
0.32
Concomitant immunosuppression, n (%)
 Prednisolone
 Azathioprine
 Mycophenolate
55 (98.2)
23 (41.1).
19 (33.9)
56 (94.9)
28 (47.5)
 6 (10.2)
0.33
0.49
<0.01
Cyclosporine trough level (ng/mL) 126 +/- 44 126 +/- 25 0.99
Tacrolimus trough level (ng/mL) 6.3 +/- 1.3 6.3 +/- 1.4 0.99
Median serum creatinine (umol/L) 114 (68-271) 104 (66-261) 0.71
eGFR (ml/min/1.73m2) 58 +/- 19 57 +/- 19 0.84
Amount of proteinuria (g/day) 0.18 +/- 0.19 0.28 +/- 0.33 0.20
CNI: calcineurin inhibitor; ESRD: end stage renal disease; eGFR: estimated glomerular filtration rate
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cancer already had advanced disease during diagnosis. 
Five patients died of carcinoma of lung, 2 carcinoma of 
colon, 1 carcinoma of esophagus, 1 carcinoma of breast, 
1 renal cell carcinoma, 1 nasopharyngeal carcinoma and 
1 carcinoma of ovary. On the other hand, 22 patients 
who died in the non-conversion group had advanced 
cancers (5 PTLD, 4 colon, 4 liver, 2 stomach, 2 lung, 1 
breast, 1 prostate, 1 pancreas, 1 kaposi sarcoma and 1 
oral cavity) while 2 patients had cancer recurrence (1 
liver and 1 esophagus). The 1-year and 3-year patient 
survival in mTOR inhibitor group were 80.4% and 52.0% 
respectively while the 1-year and 3-year patient survival in 
non-conversion group were 83.0% and 44.7% respectively 
(P = 0.17). On the other hand, 5 patients had graft failure 
(2 due to chronic allograft nephropathy and 3 due to 
unknown causes) in the mTOR inhibitor group and 11 
patients lost their grafts (1 due to acute antibody-mediated 
rejection and 10 had chronic allograft nephropathy) in the 
non-conversion group. For the 2 patients who had chronic 
allograft nephropathy in the mTOR inhibitor group, 1 
patient already had eGFR less than 30ml/min/1.73m2 
during conversion while the other patient had graft 
failure 5 years after conversion to mTOR inihibitor. The 
1-year and 3-year death-censored graft survival in mTOR 
inhibitor group were 97.9 % and 90.3% respectively while 
the 1-year and 3-year death-censored graft survival in non-
conversion group were 93.2% and 80.2% respectively (P 
= 0.17).
There was no significant difference in the 
distribution of hematological malignancies and solid 
organ cancers in both treatment arms (Table 2). If we just 
focused on those patients with hematological malignancies 
(all PTLD in our cohort), there were 4 with localized 
disease and 7 with advanced disease in the mTOR 
inhibitor group while there were 1 with localized disease 
and 6 with advanced disease in the non-conversion group. 
Table 3: Change of immunosuppressive regimen before and after cancer
mTOR inhibitor
(n = 56)
Non-conversion
(n = 59)
Drug regimen before cancer, n (%)
 Pred/Aza/CsA
 Pred/Aza/FK
 Pred/MMF/CsA
 Pred/MMF/FK
 Pred/CsA
 Pred/FK
 CsA/Aza
16 (28.6)
 6 (10.7)
 8 (14.3)
11 (19.6)
11 (19.6)
 3 (5.4)
 1 (1.8)
19 (32.2)
 6 (10.2)
 1 (1.7)
5 (8.5)
20 (33.9)
 5 (8.5)
 3 (5.0)
Dosage before cancer (mg)
 Pred
 Aza
 MMF
 CsA
FK
7.5 (5.0-7.5)
50 (25-100)
1000 (500-1500)
150 (50-250)
 3.0 (1.0-5.0)
7.5 (5.0-30)
50 (25-100)
1000 (1000-1500)
 175 (100-400)
  4.0 (2.0-14)
Drug regimen after cancer, n (%)
 Pred/Aza/CsA
 Pred/Aza/FK
 Pred/MMF/CsA
 Pred/MMF/FK
 Pred/CsA
 Pred/FK
 CsA/Aza
CsA
 Pred/CsA/Sirolimus
 Pred/FK/Sirolimus
 Pred/Sirolimus
 Pred/CsA/Everolimus
 Pred/FK/Everolimus
 Pred/Everolimus
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
23 (41.1)
11 (19.6)
 1 (1.8)
10 (17.8)
 9 (16.1)
 2 (3.6)
 14 (23.7)
  3 (5.1)
  0 (0)
  3 (5.1)
 26 (44.1)
 11 (18.6)
  1 (1.7)
  1 (1.7)
  0 (0)
  0 (0)
  0 (0)
  0 (0)
  0 (0)
  0 (0)
Dosage after cancer (mg)
Pred
Aza
MMF
CsA
FK
  5.0 (5.0-7.5)
   0 (0)
   0 (0)
  50 (0-175)
  1.5 (0-4.0)
   5.0 (0-10)
   50 (0-100)
1000 (0-1000)
  150 (100-300)
   3.5 (0-4.5)
Aza: azathioprine; CsA: cyclosporine; FK: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisolone;
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There was no significant difference in the localized or 
advanced PTLD in both groups (P = 0.60). None of the 
patients with PTLD developed cancer recurrence or acute 
allograft rejection. Eight patients died (7 due to sepsis and 
1 due to ischemic heart disease) in the mTOR inhibitor 
group and 7 patients died (5 due to cancer progression 
and 1 due to sepsis) in the non-conversion group. There 
was no significant difference in patient survival (P = 0.12) 
or death-censored graft survival (P = 0.44) between both 
treatment groups. For solid organ tumors, there was also 
no significant difference in patient survival (P = 0.16), 
death-censored graft survival (P = 0.19) and cancer 
recurrence free survival (P = 0.31) between both groups 
of patients.
Five patients discontinued mTOR inhibitors within 
the first 2 years of study period because of various side 
effects, 1 due to severe aphthous and colonic ulcers, 
1 due to hemolytic uremic syndrome, 1 due to severe 
gastrointestinal upset, 1 due to interstitial lung disease 
and `1 due to increasing proteinuria. On the other hand, 
none of the patients in the non-conversion group reported 
serious side effects.
DISCUSSION
 There has been emerging data showing that mTOR 
pathway plays a significant role in the development of 
different types of cancers [11]. Although the protective 
effect of mTOR inhibitors on cancer development in 
transplant recipients has been shown in different studies 
[10, 12, 15, 16], a recent meta-analysis study by Yanik 
EL et al. showed that there was no association between 
sirolimus and the incidence of cancers after excluding 
NMSC [17]. Currently it is still not certain what would be 
the best immunosuppressive drug regimen in the kidney 
transplant recipients who developed de novo cancers. 
Different studies have demonstrated that mTOR inhibitors 
might be beneficial in the treatment of Kaposi sarcoma, 
recurrent skin cancer, PTLD and renal cell carcinoma [18]. 
The most common practice is to withdraw CNIs abruptly 
and then replace with mTOR inhibitors [6, 11]. However, 
complete avoidance or withdrawal of CNIs could be 
associated with a greater risk of acute or chronic rejection 
and graft failure [14, 19]. In addition, a retrospective study 
Figure 1: Kaplan-Meier curve showing the cancer free survival in mTOR inhibitor group and non-conversion group.
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showed that conversion to mTOR inhibitors after CNI 
withdrawal might increase the risk of developing class II 
donor-specific antibodies, which probably favor chronic 
antibody-mediated rejection and thus reduce allograft 
survival [20]. 
Unlike other studies [6, 21, 22], only 3 patients 
(5.4%) in the mTOR inhibitor group in our study had 
CNI withdrawal. Approximately 95% of patients were 
switched to the combination of prednisolone, low dose 
CNI and mTOR inhibitor. In our cohort, the trough level 
of sirolimus was 8.2 +/- 2.1 ng/mL while the trough level 
of everolimus was 4.9 +/- 1.2 ng/mL. On the other hand, 
the CNI trough level was maintained at a much lower level 
when compared with the patients in the non-conversion 
group. In the mTOR inhibitor group, the cyclosporine 
trough level was 52 +/- 17 ng/mL and the tacrolimus 
trough level was 3.6 +/- 1.0 ng/mL. Despite significant 
reduction of CNI dosage after diagnosis of cancer, the 
overall rejection rate remained low in our study. Only 
4 patients (3.5%) suffered from acute rejection (2 from 
each group) after a median follow up of 28 months and 
there was no significant difference in the rejection free 
survival between both treatment arms. Although there 
were fewer episodes of cancer recurrence (5.4% vs 11.9%) 
in the mTOR inhibitor group than in the non-conversion 
group, the difference was not statistically significant. One 
possible explanation was that the follow-up period in our 
cohort was too short to show the effectiveness of mTOR 
inhibitors in the prevention of cancer recurrence.
The eGFR of patients in the mTOR inhibitor group 
at both 6-month and 1-year was similar to those in the non-
conversion group. The lack of significant improvement in 
renal function in the mTOR inhibitor group could be the 
result of the relatively late mTOR inhibitor conversion in 
our cohort (mean 10.4 years). In addition, another study 
also showed that eGFR improvement was less among 
patients who had mTOR inhibitor conversion due to 
cancers when compared with those who had conversion 
due to chronic graft dysfunction [23].
In the mTOR inhibitor group, all patients who died 
of cancer progression were due to advanced-stage solid 
organ tumors. On the other hand, none of the patients with 
PTLD (n = 11) died of malignancies. This is in contrast 
to the patients with PTLD in the non-conversion group (n 
= 7) where 5 of them died of cancer progression. It is not 
clear whether this discrepancy could be due to the potent 
anti-proliferative effect of mTOR inhibitors. However, it 
seems that mTOR inhibitors were less effective in patients 
with advanced stage or disseminated solid organ cancers. 
In addition, the optimal dose of mTOR inhibitors for 
treatment of various tumors remains unknown and the 
failure of treatment in some cancers could be the result 
from the lower dose of mTOR inhibitors used in our 
cohort.
The major limitations of this study included 
retrospective design and heterogeneity of different types 
and stages of cancers which made it difficult to compare 
our results with other studies. In addition, we could not 
analyze sirolimus and everolimus individually because 
of the low overall rate of mTOR inhibitor use. Since 
the number of patients with post-transplant cancers is 
relatively small, it is highly unlikely that a prospective, 
randomized trial with an adequate sample size and 
duration of follow-up can be performed to detect the 
differences of using mTOR inhibitor in these patients. 
As a result, retrospective studies based on institutional 
experiences, such as our study, are still an attractive 
option for providing further knowledge about the role of 
mTOR inhibitor for preventing or treating post-transplant 
cancers. In fact, our study has already recruited the largest 
number of kidney transplant recipients who had mTOR 
inhibitor conversion due to post-transplant cancers. 
Moreover, the presence of a control group in our study 
allows comparisons between patients converted to mTOR 
inhibitors and those remained on CNI-based therapy.
 In conclusion, it is still uncertain whether 
conversion to mTOR inhibitors after cancer development 
will have any benefit in long-term patient and graft 
survival in kidney transplant recipients. Our study 
shows that use of mTOR inhibitors together with CNI 
minimization may be able to offer a reasonable option 
in view of the relatively stable renal function, very low 
Table 4: Renal function and amount of proteinuria after cancers
mTOR inhibitor
(n = 56)
Non-conversion
(n = 59) P value
Median serum creatinine (umol/L)
 6-month
1-year 113 (62-321)119 (45-815)
107 (57-334)
106 (66-355)
0.71
0.32
eGFR (ml/min/1.73m2)
 6-month
1-year
59 +/- 21
58 +/- 29
59 +/- 22
54 +/- 20
0.99
0.50
Proteinuria, 1-year (g/day) 0.68 +/- 0.92 0.38 +/- 0.56 0.17
CsA trough level (ng/mL) 52 +/- 17 75 +/- 23 <0.01
FK trough level (ng/mL) 3.6 +/- 1.0 4.6 +/- 1.3 0.04
CsA: cyclosporine; eGFR: estimated glomerular filtration rate; FK: tacrolimus
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rejection rate and low cancer recurrence rate. However, 
treatment should also be individualized according to the 
different clinical condition in each patient. Further studies, 
especially on the optimal dose of mTOR inhibitors in post-
transplant solid organ tumors, are required.
MATERIALS AND METHODS
This was a retrospective study of all kidney 
transplant recipients who were diagnosed to have post-
transplant cancers and had been followed up in 2 large 
transplant centers in Hong Kong, namely Queen Elizabeth 
Hospital and Queen Mary Hospital, between the period 
1/1/1994 and 30/6/2015. This study was approved by 
the research ethics committee. All cancer events were 
collected from the Hong Kong Renal Registry database. 
The Renal Registry is a direct, online, computerized 
registry system developed by the Central Renal 
Committee, Hospital Authority (HA), to collect data of 
all patients who received renal replacement therapy under 
HA. The data is entered directly by renal doctors or nurses 
of the individual renal unit and each unit can access their 
own patient data [24]. It is therefore an accurate and up-
to-date record of all comorbidities and complications of 
all renal replacement therapy patients including kidney 
transplant recipients managed under the HA. All cancers 
were diagnosed and verified with histology and other 
relevant information, such as radiological imaging, and 
coded according to the 10th World Health Organization 
International Classification of Disease (WHO ICD-10). 
All basic demographic and clinical data were extracted 
patients’ medical record. 
All patients in our study received CNIs, 
either tacrolimus or cyclosporine, as part of the 
maintenance immunosuppressive therapy after kidney 
transplantation. . When cancer was diagnosed, the dose 
of immunosuppressive drugs was reduced. Starting from 
2006, those kidney transplant recipients with newly 
diagnosed cancers would have their immunosuppressive 
regimen converted to an mTOR inhibitors (either sirolimus 
or everolimus)-based therapy which consisted of abrupt 
withdrawal of mycophenolate / azathioprine together with 
either CNI minimization or elimination. However, mTOR 
inhibitors would not be considered in those patients 
who refused conversion therapy. As a result, the kidney 
transplant recipients with de novo cancers were divided 
into 2 groups; namely mTOR inhibitor group (conversion 
to either sirolimus or everolimus after cancer) and non-
conversion group. In mTOR inhibitor group, the initial 
doses of sirolimus and everolimus were 2 mg per day and 
0.75 mg twice daily respectively. The doses of sirolimus 
and everolimus were then adjusted according to the whole 
blood trough concentration. The target range was 5-10 
ng/mL for sirolimus and 3-8 ng/mL for everolimus. The 
CNI doses were concurrently reduced to reach our target 
trough levels of 3-5 ng/mL for tacrolimus and 50-80 ng/
mL for cyclosporine. The outcome included the allograft 
function, patient survival, graft survival, acute rejection 
and cancer recurrence. Changes in allograft function were 
determined by comparing serum creatinine level and 
estimated glomerular filtration rate (eGFR) at 6 month 
and 1 year after diagnosis of cancers to that at the time of 
diagnosis. eGFR is calculated by the abbreviated MDRD 
equation : 186 x (Creatinine / 88.4)-1.154 x (Age)-0.203 x 
(0.742 if female) x (1.210 if black) [25].
In order to study the effects of mTOR inhibitors in 
patients with established cancers, patients who already 
received mTOR inhibitors before cancers were excluded. 
For solid organ cancers, localized disease was defined as 
those cancers confined to the primary site of organ while 
advanced disease was defined for those with lymph node 
or distant metastasis. For hematological malignancies, 
localized disease was defined as involving single 
lymph node region while advanced disease was defined 
as involving 2 or more lymph node regions or extra-
lymphatic organs.
Statistical analyses
SPSS (SPSS 20.0, Inc., Chicago, IL USA) was used 
to perform the statistical analyses. Continuous data were 
either expressed as mean +/- standard deviation (SD) or 
median (range) and categorical data were expressed as 
percentages. Categorical data were compared with chi-
square or Fishers exact tests while continuous data were 
compared with t-test.or Mann-Whitney U test. .Log rank 
test and Kaplan Meier survival analysis were used to 
compare the patient survival, graft survival, rejection free 
survival and cancer free survival after diagnosis of cancer 
between the 2 groups. For purposes of the analyses and 
defining years of follow-up, patients were censored at the 
time of event, the date of death, the last reported contact 
or 31st December 2015. A P-value of less than 0.05 was 
defined as statistically significant.
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